Promising Interim Results from iTeos Therapeutics' Study
iTeos Therapeutics, Inc. (NASDAQ: ITOS) recently announced some encouraging interim results from their crucial GALAXIES Lung-201 study. This clinical trial aims to assess how effective the combination therapy of belrestotug and dostarlimab is for patients dealing with advanced non-small cell lung cancer (NSCLC) who have high PD-L1 levels. The findings highlighted an impressive objective response rate (ORR) ranging from 63.3% to 76.7%, indicating substantial efficacy for this group of patients.
Insights from the GALAXIES Lung-201 Study
According to the latest data cut-off, the study involved 124 patients who were evaluated for both safety and efficacy. A striking difference of over 30% in confirmed ORR was reported between the treatment group receiving the combination of belrestotug and dostarlimab and the group treated with dostarlimab alone. This finding underscores the potential of employing TIGIT:PD-1 doublet therapy, presenting it as a strong option compared to traditional therapies.
Expert Reactions to the Findings
Dr. Michel Detheux, CEO of iTeos, expressed optimism about these results. He mentioned that achieving a consistent confirmed ORR of around 60% across three different dosages of the combination shows significant promise for improved outcomes in patients with limited treatment options. Furthermore, the clinical improvements regarding tumor response rates are particularly uplifting.
Insights on Treatment Options
Dr. Brian Henick from Columbia University highlighted the ongoing effort to find patient-centered treatment options as vital for addressing this serious condition. The interim data from the GALAXIES Lung-201 study reflects meaningful progress, suggesting that the combination of belrestotug and dostarlimab may become a compelling alternative for treating NSCLC.
Overview of Trial Design and Efficacy Evaluation
The GALAXIES Lung-201 study is structured to compare new immunotherapy combinations with standard treatments for patients with advanced lung cancer. Treatment arms include various combinations, such as pembrolizumab monotherapy, dostarlimab monotherapy, and the powerful combination of belrestotug and dostarlimab.
This study primarily aims to measure the ORR as assessed by investigators, while secondary objectives focus on evaluating safety, progression-free survival, and overall survival metrics. Some patients have exhibited a significant reduction in ctDNA across different dosages, further underscoring the effectiveness of combining belrestotug and dostarlimab.
Safety Profile Aligns with Previous Findings
Throughout the study, the safety profile of belrestotug in combination with dostarlimab has remained consistent with what’s been previously reported for checkpoint inhibitors. While some immune-related adverse events did occur with the combination therapy, they were reported as manageable.
Upcoming Conference to Explore Findings
iTeos Therapeutics plans to host a conference call to discuss the findings and significance of the GALAXIES Lung-201 study in more detail. Attendees will have the chance to hear directly from the research team about these exciting developments and the ongoing studies in the pipeline.
About iTeos Therapeutics
iTeos Therapeutics is committed to advancing the development of next-generation immuno-oncology therapies for serious health challenges. With a solid understanding of tumor immunology, the company is dedicated to providing innovative solutions to patients in need. Their clinical pipeline includes various projects aimed at addressing critical immunosuppressive pathways, focusing on promising therapeutic candidates.
Frequently Asked Questions
What were the key findings of the GALAXIES Lung-201 study?
The study found an objective response rate of 63.3% to 76.7% with the combination of belrestotug and dostarlimab, showing significant efficacy when compared to dostarlimab monotherapy.
Who is the CEO of iTeos Therapeutics?
Dr. Michel Detheux is the president and CEO of iTeos Therapeutics, overseeing the company’s innovative therapies and trials.
What does the term PD-L1 high indicate?
PD-L1 high means that a tumor shows elevated levels of programmed death-ligand 1, which can be effectively targeted by specific therapies like belrestotug and dostarlimab.
How is the safety of the combination therapy characterized?
The safety profile of the belrestotug and dostarlimab combination aligns with known profiles of checkpoint inhibitors, with any adverse events being manageable.
When is the follow-up data expected?
iTeos Therapeutics anticipates further follow-up data from this trial in the upcoming years, especially for insights expected in 2025.
